Nevada lawmaker urges Purdue to unveil prescribers list; GSK splits U.K., Ireland business ahead of drink brands sale;

@FiercePharma: Eli Lilly's $15B battle for longer Alimta monopoly hits court today. Article | Follow @FiercePharma

@EricPFierce: India to consider putting handcuffs on foreign investment to protect domestic generics market. Story | Follow @EricPFierce

@CarlyHFierce: Merck stops selling Zilmax to study livestock drug's safety; the drug added $159M to sales in 2012. News | Follow @CarlyHFierce

> Nevada State Sen. Richard Segerblom has joined calls for Purdue Pharma to hand over a list of doctors suspected of recklessly prescribing its addictive painkiller OxyContin. Report

> GlaxoSmithKline ($GSK) has split its U.K. and Ireland businesses and named leadership teams for each to prepare for its planned divestment of the drink brands Lucozade and Ribena. Report

> Health Canada has approved ThromboGenics' eye drug Jetrea to treat symptomatic vitreomacular adhesion. Report

> India's Lupin is looking for branded drugs to buy in the United States. Report

> A Novartis ($NVS) executive in India scolded the country's recent intellectual property moves, saying the revocation of patents and issuance of compulsory licenses creates uncertainty and undermines R&D investment. Report

Medical Device News

@FierceMedDev: Special report: Device-tax worries aside, major med tech mostly added jobs in 2012. Feature | Follow @FierceMedDev

@DamianFierce: How can early-phase CROs brave a tough market? We asked two of the biggest. Editor's corner | Follow @DamianFierce

@MarkHFierce: Orthofix is in trouble again, this time for not filing its financials on time. Press release | Follow @MarkHFierce

@MichaelGFierce: Last week's Chutes & Ladders roundup: Pharma veteran Jeffrey Jonas takes top spot at Sage & more in biotech/pharma hirings. More | Follow @MichaelGFierce

> Abbott closes $250M deal for eye surgery biz. Article

> St. Jude snags Endosense for up to $331M. Report

> Cigna policy change risks hammering Myriad's Dx bottom line. Story

Biotech News

@FierceBiotech: Will the biotech dealmaking lull extend through the rest of the year? More | Follow @FierceBiotech

@JohnCFierce: Novartis lashes out at India's patent rulings, says country is losing R&D. But India clearly doesn't care about R&D. More | Follow @JohnCFierce

@RyanMFierce: Pfizer's social head touted some of the internal and external feats of the pharma giant. Article | Follow @RyanMFierce

@EmilyMFierce: Inovio vaccine kills malaria, boosts immune response in animals. Story | Follow @EmilyMFierce

> GTx shares eviscerated after muscle drug flops in PhIII cancer studies. Story

> New DMD data gives Sarepta an edge in GlaxoSmithKline showdown. Article

> Analyst lays out worst-case scenario for Dendreon. Item

CRO News

> Quintiles buying Novella with eye on emerging biotechs. More

> AMRI's shares crater as partner Bristol-Myers ditches depression drug. Article

> Risk-based monitoring could be a boon to CROs. Item

> Boehringer pulls plug on VA commercial plant. Story

> Express Scripts sells CRO biz to private equity outfit. More

> WuXi ratchets up expectations after banner quarter. News

> AMRI's shares crater as partner Bristol-Myers ditches depression drug. Report

Biotech IT News

> RTI wins NIH support to advance web-based toolkit for genetics research. News

> India's InterpretOmics scores $1.6M round to fuel bioinformatics biz. Report

> Pfizer taps online marketplace for outsourcing research. Story

> FDA's former IT boss nails down industry gig. More

> Certara, provider of drug research software, buys Michigan rival. Article

And Finally... The U.S. obesity rate is growing more slowly than in years past, but "extreme" obesity has risen dramatically. Report